Filtered By:
Cancer: Breast Carcinoma

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 244 results found since Jan 2013.

Silencing of TMSG1 enhances metastasis capacity by targeting V-ATPase in breast cancer.
In conclusion, silencing of TMSG1 increased V-ATPase activity, decreased extracellular pH and in turn the activation of secreted MMP-2, which ultimately promoted metastasis capacity of breast cancer cell. PMID: 25973015 [PubMed - in process]
Source: Clinical Genitourinary Cancer - May 17, 2015 Category: Cancer & Oncology Authors: Zi Y, Zhao W, Zhou J, He H, Xie M Tags: Int J Clin Exp Pathol Source Type: research

BRCA2 protects mammalian cells from heat shock.
CONCLUSION: BRCA2 has a protecting role against heat-induced cell death. BRCA2 might be a potential molecular target for hyperthermic cancer therapy. PMID: 28891354 [PubMed - as supplied by publisher]
Source: International Journal of Hyperthermia - September 13, 2017 Category: Internal Medicine Tags: Int J Hyperthermia Source Type: research

Effects of forkhead Box protein A1 on cell proliferation regulating and EMT of cervical carcinoma.
CONCLUSIONS: FOXA1 expression increased in cervical cancer. Inhibition of FOXA1 expression blocked the proliferation of cervical cancer, promoted tumor cell apoptosis, suppressed the occurrence of EMT and VEGF production, and can regulate cervical cancer metastasis. FOXA1 can be used as a new molecular biological target for cervical cancer diagnosis and treatment. PMID: 30468461 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - November 24, 2018 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

PGC1 β Regulates Breast Tumor Growth and Metastasis by SREBP1-Mediated HKDC1 Expression
Conclusions: PGC1β regulates breast cancer tumor growth and metastasis by SREBP1-mediated HKDC1 expression. This provides a novel therapeutic strategy through targeting the PGC1β/HKDC1 signaling pathway for breast cancer treatment. Introduction Breast cancer is a very common cancer with significant premature mortality in women. Around 12% of women in USA will have chance to be diagnosed with breast cancer during their lifetimes (1, 2). The development of breast cancer is regulated by many factors, and even as average survival rates have increased significantly as a result of many advanced treatments...
Source: Frontiers in Oncology - April 16, 2019 Category: Cancer & Oncology Source Type: research

Silencing of ETS1 reverses adriamycin resistance in MCF-7/ADR cells via downregulation of MDR1
Conclusions: This study demonstrates that drug resistance can be effectively reversed in adriamycin-resistant breast carcinoma cells through delivery of siRNAs targeting ETS1.
Source: Cancer Cell International - March 7, 2014 Category: Cancer & Oncology Authors: Jinrong WeiYong ZhouGuo-Qin JiangDong Xiao Source Type: research

Downregulation of clusterin mediates sensitivity to protein kinase inhibitors in breast cancer cells
We describe the use of clusterin-specific antisense oligonucleotides and siRNA to sensitize breast carcinoma cells to several PKIs. MCF-7 and MDA-MB-231 cells were treated with antisense oligonucleotide or siRNA to clusterin and the following PKIs: H-89, chelerythrine and genistein. The three inhibitors used in this study upregulated clusterin expression and treatments that included antisense oligonucleotide or siRNA to clusterin reduced the number of viable cells more effectively than did treatment with the drugs alone. Therefore, treatment with such combinations may benefit patients with breast cancer.
Source: Anti-Cancer Drugs - November 27, 2014 Category: Cancer & Oncology Tags: Preclinical Reports Source Type: research

P6.15 * peroxiredoxin 3 as a molecular therapeutic target in breast cancer
Conclusion: Our data suggests that PRDX3 promotes breast tumorigenesis and could be a potential therapeutic target in breast cancer.
Source: Annals of Oncology - March 20, 2015 Category: Cancer & Oncology Authors: Chua, P. J., Chin, J., Chee, S., Thike, A. A., Yip, G., Tan, P. H., Bay, B. H. Tags: Poster session 6: New drugs/targets: other Source Type: research

17β-estradiol induces stearoyl-CoA desaturase-1 expression in estrogen receptor-positive breast cancer cells
Conclusions: This study illustrates for the first time that, in contrast to hepatic and adipose tissue, estrogen induces SCD-1 expression and activity in breast carcinoma cells. These results support SCD-1 as a therapeutic target in estrogen-sensitive breast cancer.
Source: BMC Cancer - May 29, 2015 Category: Cancer & Oncology Authors: Anissa BelkaidSabrina DuguayRodney OuelletteMarc Surette Source Type: research

Knockdown of ROS1 gene sensitizes breast tumor growth to doxorubicin in a syngeneic mouse model.
Abstract Treatment of breast cancer, the second leading cause of female deaths worldwide, with classical drugs is often accompanied by treatment failure and relapse of disease condition. Development of chemoresistance and drug toxicity compels compromising the drug concentration below the threshold level with the consequence of therapeutic inefficacy. Moreover, amplification and over-activation of proto-oncogenes in tumor cells make the treatment more challenging. The oncogene, ROS1 which is highly expressed in diverse types of cancers including breast carcinoma, functions as a survival protein aiding cancer progr...
Source: International Journal of Oncology - March 22, 2016 Category: Cancer & Oncology Authors: Tiash S, Chua MJ, Chowdhury EH Tags: Int J Oncol Source Type: research

Evaluation of in vitro and in vivo therapeutic antitumor efficacy of transduction of polo-like kinase 1 and heat shock transcription factor 1 small interfering RNA.
Authors: Hattori Y, Kikuchi T, Ozaki KI, Onishi H Abstract Mitotic progression is regulated by the phosphorylation of heat shock transcription factor 1 (HSF1) by polo-like kinase 1 (PLK1); however, this interaction is often deregulated in tumors. High expression levels of PLK1 and HSF1 have been observed in various types of human cancer. In the present study, it was investigated whether small interfering (si)RNA against PLK1 or HSF1 could suppress tumor growth in vitro and in vivo. In vitro transfection of PLK1 and HSF1 siRNA into PKL1- and HSF1-positive human breast tumor MDA-MB-231 and human cervical carcinoma He...
Source: Experimental and Therapeutic Medicine - October 28, 2017 Category: General Medicine Tags: Exp Ther Med Source Type: research

Inhibition of rapamycin-induced Akt phosphorylation by cotylenin A correlates with their synergistic growth inhibition of cancer cells.
In this study, we found that cotylenin A could suppress rapamycin-induced phosphorylation of Akt (Ser473) in MCF-7 cells and lung carcinoma A549 cells and that cotylenin A also enhanced the rapamycin-induced growth inhibition of MCF-7 and A549 cells. ISIR-005 (a synthetic cotylenin A-derivative) was able to enhance rapamycin‑induced growth inhibition and could also markedly inhibit rapamycin-induced phosphorylation of Akt. We also found that the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) or arsenic trioxide (ATO) in combination with rapamycin markedly inhibited the growth of MCF-7 cells and 17-AA...
Source: International Journal of Oncology - December 19, 2012 Category: Cancer & Oncology Authors: Kasukabe T, Okabe-Kado J, Haranosono Y, Kato N, Honma Y Tags: Int J Oncol Source Type: research

CD44/cellular prion protein interact in multidrug resistant breast cancer cells and correlate with responses to neoadjuvant chemotherapy in breast cancer patients
Abstract Multidrug resistance (MDR) is one of the most important factors leading to chemotherapeutic failure in patients with breast cancer. The invasive/metastatic ability of MDR cells is strengthened compared with their parental cells. However, the mechanisms underlying MDR have not been fully elucidated. We found that CD44 and the cellular prion protein (PrPc) were both overexpressed in MDR cells (MCF7/Adr and H69AR). Subsequently, we chose the human breast cancer cell line MCF7/Adr, which is resistant to adriamycin, for further research. We discovered that PrPc physically and functionally interacted with CD44. The knoc...
Source: Molecular Carcinogenesis - May 16, 2013 Category: Molecular Biology Authors: Yuanyuan Cheng, Lili Tao, Jiawen Xu, Qingquan Li, Juan Yu, Yiting Jin, Qi Chen, Zude Xu, Qiang Zou, Xiuping Liu Tags: Research Article Source Type: research

Targeting Fyn in Ras‐transformed cells induces F‐actin to promote adherens junction‐mediated cell–cell adhesion
Fyn, a member of the Src family kinases (SFK), is an oncogene in murine epidermis and is associated with cell–cell adhesion turnover and induction of cell migration. Additionally, Fyn upregulation has been reported in multiple tumor types, including cutaneous squamous cell carcinoma (cSCC). Introduction of active H‐Ras(G12V) into the HaCaT human keratinocyte cell line resulted in upregulation of Fyn mRNA (200‐fold) and protein, while expression of other SFKs remained unaltered. Transduction of active Ras or Fyn was sufficient to induce an epithelial‐to‐mesenchymal transition in HaCaT cells. Inhibition of Fyn acti...
Source: Molecular Carcinogenesis - June 29, 2014 Category: Molecular Biology Authors: Sarah E. Fenton, Kelli A. Hutchens, Mitchell F. Denning Tags: Research Article Source Type: research

Trefoil factor 3 promotes metastatic seeding and predicts poor survival outcome of patients with mammary carcinoma AU Query: Please confirm the address additions or amend accordingly.
Conclusions: TFF3 expression predicts metastasis and poor survival outcome of patients with MC and functionally stimulates cellular invasion and metastasis of ER?+?MC cells. Adjuvant functional inhibition of TFF3 may therefore be considered to ameliorate outcome of ER?+?MC patients.
Source: Breast Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Vijay PandeyZheng-Sheng WuMin ZhangRui LiJian ZhangTao ZhuPeter Lobie Source Type: research

The basal epithelial marker P-cadherin associates with breast cancer cell populations harboring a glycolytic and acid-resistant phenotype
Conclusions: Our results establish a link between aberrant P-cadherin expression and hypoxic, glycolytic and acid-resistant breast cancer cells, suggesting a possible role for this marker in cancer cell metabolism.
Source: BMC Cancer - October 1, 2014 Category: Cancer & Oncology Authors: Bárbara SousaAna RibeiroAna NobreNair LopesDiana MartinsCéline PinheiroAndré VieiraAndré AlbergariaRené GerhardFernando SchmittFátima BaltazarJoana Paredes Source Type: research